MDCG 2020-3 Rev.01 Published – Significant Change Guidance 👍
Key points:
🔹 Clinical evaluation: The definition of clinical evaluation has been clarified.
🔹 Postmarket surveillance: The requirements for postmarket surveillance have been strengthened.
🔹 Risk management: The requirements for risk management have been clarified.
🔹 Clinical data: The requirements for clinical data have been clarified.
🔹 Software: The requirements for software have been clarified.
🔗 Original Document: https://health.ec.europa.eu/system/files/2023-05/mdcg_2020-3_en.pdf